Quick Answer
BIOGEN INC. reported Total Revenue of $9.89 billion for fiscal year 2025.
BIOGEN INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.89B +2.2% |
$9.68B -1.6% |
$9.84B -3.3% |
$10.17B -7.4% |
$10.98B -18.3% |
$13.44B -6.5% |
| Net Income | $1.29B -20.8% |
$1.63B +40.6% |
$1.16B -61.9% |
$3.05B +95.8% |
$1.56B -61.1% |
$4.00B -32.1% |
| Diluted EPS | $8.79 -21.4% |
$11.18 +40.3% |
$7.97 -61.8% |
$20.87 +100.7% |
$10.40 -58.1% |
$24.80 -21.1% |
| Total Assets | $29.44B +5.0% |
$28.05B +4.5% |
$26.84B +9.3% |
$24.55B +2.8% |
$23.88B -3.0% |
$24.62B -9.6% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | — | — | — | $6.28B +0.1% |
$6.27B -15.5% |
$7.43B +66.5% |
| Stockholders Equity | $18.26B +9.2% |
$16.72B +13.0% |
$14.80B +10.5% |
$13.40B +23.0% |
$10.90B +1.8% |
$10.70B -19.8% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | — | — | — | — | $2.84B -37.6% |
$4.55B -35.4% |
| Shares Outstanding | 146.80M +0.7% |
145.80M +0.6% |
144.90M +0.6% |
144.00M -2.0% |
147.00M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.53B | +2.8% | -4.2% |
| Net Income | September 30, 2025 | $466.50M | +20.1% | -26.5% |
| Diluted EPS | September 30, 2025 | $3.17 | +19.2% | -26.8% |
| Total Assets | September 30, 2025 | $29.21B | +3.2% | +3.1% |
| Cash and Equivalents | September 30, 2019 | $2.34B | -1.8% | +36.0% |
| Long-Term Debt | September 30, 2025 | $6.29B | +38.3% | +0.0% |
| Stockholders Equity | September 30, 2025 | $18.21B | +11.3% | +3.3% |
| R&D Expense | March 31, 2013 | $284.34M | -20.1% | -6.5% |
| Operating Income | March 31, 2022 | $610.70M | -37.3% | -23.1% |
- BIOGEN INC. reported Total Revenue of $9.89 billion for fiscal year 2025.
- BIOGEN INC. showed an increase of +2.2% in Total Revenue compared to the prior fiscal year.
- BIOGEN INC. reported Net Income of $1.29 billion for fiscal year 2025.
- BIOGEN INC. showed a decrease of -20.8% in Net Income compared to the prior fiscal year.
- BIOGEN INC. reported Diluted EPS of $8.79 per share for fiscal year 2025.
- BIOGEN INC. showed a decrease of -21.4% in Diluted EPS compared to the prior fiscal year.
- BIOGEN INC. reported Total Assets of $29.44 billion for fiscal year 2025.
- BIOGEN INC. showed an increase of +5.0% in Total Assets compared to the prior fiscal year.
- BIOGEN INC. reported Cash and Equivalents of $2.91 billion for fiscal year 2019.
- BIOGEN INC. showed an increase of +137.9% in Cash and Equivalents compared to the prior fiscal year.
- BIOGEN INC. reported Long-Term Debt of $6.28 billion for fiscal year 2022.
- BIOGEN INC. showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- BIOGEN INC. reported Stockholders Equity of $18.26 billion for fiscal year 2025.
- BIOGEN INC. showed an increase of +9.2% in Stockholders Equity compared to the prior fiscal year.
- BIOGEN INC. reported R&D Expense of $1.33 billion for fiscal year 2012.
- BIOGEN INC. showed an increase of +9.5% in R&D Expense compared to the prior fiscal year.
- BIOGEN INC. reported Operating Income of $2.84 billion for fiscal year 2021.
- BIOGEN INC. showed a decrease of -37.6% in Operating Income compared to the prior fiscal year.
- BIOGEN INC. reported Shares Outstanding of 146.80 million shares for fiscal year 2025.
- BIOGEN INC. showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: